



PRESS RELEASE
For immediate release

**PERCEPTRONIX TO EXHIBIT AT CANADIAN ASSOCIATION OF GENERAL
PRACTITIONERS IN ONCOLOGY**

VANCOUVER, CANADA (October 22, 2008) – Perceptronix Medical Inc., an independent quantitative cytology laboratory specializing in early cancer diagnosis, is honoured to be a bronze sponsor for the Canadian Association of General Practitioners In Oncology (CAGPO) Annual Conference. The company will be exhibiting at booth 15 during the CAGPO meeting from October 24 - 26, 2008 in Kelowna, BC. Perceptronix, along with distribution partner Independent Respiratory Services Inc., will be showcasing LungSign™, an innovative early lung cancer test currently available for lung cancer risk assessment.

LungSign™ is the first test to market to offer a safe, painless and convenient method of assessing a patient's risk of lung cancer. It is based on an automated quantitative cytology analysis of sputum. LungSign™ also serves as a highly relevant and useful complement to current radiological diagnostic methods (e.g. CT).

About Perceptronix Medical Inc.

Perceptronix Medical Inc ("Perceptronix" or the "Company") is a privately owned, independent cytology laboratory and cancer diagnostics company specializing in the provision of innovative early cancer detection tests based on quantitative cytology. The Company's DNA image cytometry technology was developed in partnership with the British Columbia Cancer Agency (BCCA) in Vancouver. Quantitative cytology provides physicians with an improved cytopathology assessment based on an objective measure of large-scale DNA abnormality that can indicate precancerous or cancerous changes. In addition to general quantitative cytology services, the company has developed innovative tests for the early detection of lung cancer and oral cancer.

For further information contact:

Bojana Turic, MD

President & CEO

Perceptronix Medical Inc.

555 West 8th Avenue,

Vancouver, British Columbia

V5Z 1C6.

Phone: 604-629-8785

Email: bturic@perceptronix.com